Literature DB >> 14766874

Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.

Carmen de Mendoza1, Ellen Paxinos, Pablo Barreiro, Nuria Camino, Marina Núñez, Vincent Soriano.   

Abstract

A total of 76 patients discontinued treatment with didanosine plus hydroxyurea after 1 year of maintenance therapy. The greatest human immunodeficiency virus (HIV)-RNA rebounds were seen in 10 patients harboring an L74V mutation, and the presence of viruses with this mutation rapidly waned. In contrast, viral rebounds were significantly less pronounced (P < 0.01) in 12 subjects harboring thymidine-associated mutations; these mutations persisted in all instances. Thus, selection of an L74V mutation during didanosine therapy may compromise HIV replication in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14766874      PMCID: PMC344444          DOI: 10.1128/JCM.42.2.862-866.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy.

Authors:  P Barreiro; C de Mendoza; V Soriano; J González-Lahoz
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

3.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

Authors:  D V Havlir; N S Hellmann; C J Petropoulos; J M Whitcomb; A C Collier; M S Hirsch; P Tebas; J P Sommadossi; D D Richman
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

4.  3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.

Authors:  R M Gulick; J W Mellors; D Havlir; J J Eron; A Meibohm; J H Condra; F T Valentine; D McMahon; C Gonzalez; L Jonas; E A Emini; J A Chodakewitz; R Isaacs; D D Richman
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

5.  The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

Authors:  F García; M Plana; G M Ortiz; S Bonhoeffer; A Soriano; C Vidal; A Cruceta; M Arnedo; C Gil; G Pantaleo; T Pumarola; T Gallart; D F Nixon; J M Miró; J M Gatell
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

6.  Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.

Authors:  Javier Martinez-Picado; Kristina Morales-Lopetegi; Terri Wrin; Julia G Prado; Simon D W Frost; Christos J Petropoulos; Bonaventura Clotet; Lidia Ruiz
Journal:  AIDS       Date:  2002-04-12       Impact factor: 4.177

7.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the her study.

Authors:  V E Stone; J W Hogan; P Schuman; A M Rompalo; A A Howard; C Korkontzelou; D K Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2001-10-01       Impact factor: 3.731

9.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Authors:  S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

10.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

Authors:  S G Deeks; T Wrin; T Liegler; R Hoh; M Hayden; J D Barbour; N S Hellmann; C J Petropoulos; J M McCune; M K Hellerstein; R M Grant
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

View more
  1 in total

Review 1.  Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Mark A Wainberg; Bluma G Brenner; Dan Turner
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.